Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drug Pricing

Reports

Displaying 21 - 30 of 37. 10 per page. Page 3.

Advanced Search
ASPE Issue Brief

Medicare Part D: Competition and Generic Drug Prices, 2007-2018

The United States relies on the interactions of private entities – drug manufacturers, health plans and pharmaceutical benefit managers (PBMs) - to achieve value by negotiating prices, operating formularies and implementing other benefit management strategies. The U.S. does not establish or negotiate prices for prescription drugs, as do some other countries. A critical part of the U.S.

Comparing Insulin Prices in the U.S. to Other Countries

Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach.
Report to Congress

Report to Congress: Prescription Drugs: Innovation, Spending, and Patient Access

This Report responded to a request from the House and Senate Committees on Appropriations.
Report to Congress

Report to Congress: Prescription Drug Pricing Report

The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.

Comparison of U.S. and International Prices for Top Medicare Part B Drugs by Total Expenditures

The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.
ASPE Data Point

Data Point: Savings Available Under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D

ASPE analyzed Part D prescription drug event data from 2016 to estimate spending on brand drugs with generic therapeutic equivalents.

Medicare Part B Drugs: Pricing and Incentives

Medicare Part B covers infusible and injectable drugs and biologics administered in physician offices and hospital outpatient departments; as well as certain other drugs required by law provided by suppliers such as pharmacies The Part B payment method provides weak incentives for physicians to consider value – that is choose the lowest cost therapy to effectively treat a patient.
ASPE Issue Brief

Medicare Part B Reimbursement of Prescription Drugs

ASPE ISSUE BRIEF

Health Care Cost Containment and Medical Innovation

ASPE ISSUE BRIEF Health Care Cost Containment and Medical Innovation May 2012 By: Amber Jessup, Ph.D.

A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings

This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available.